TCRT

Alaunos Therapeutics Inc

$1.89

+0.04 (+2.16%)

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

0.4053

52 wk hi

2.43

Cash

$68.3M

Burn Rate (Qtr)

$7.8M

Mkt Cap

$408.6m

Avg Volume

1,648,377

*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Ad-RTS-hIL-12 + veledimex (Controlled IL-12)

Glioblastoma, Cancer

Phase 2

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

TCR-T targeting neoantigens

Solid tumor/s, Cancer

Phase 1/2

Interim update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Ad-RTS-hIL-12 + veledimex (Controlled IL-12)

Glioblastoma, Cancer

Phase 1/2

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Ad-RTS-hIL-12 + veledimex (Controlled IL-12)

Glioblastoma, Cancer

Phase 1

Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

TCRT

BPIQ_Logo_RGB-01.jpg

Company Profile

Alaunos Therapeutics (previously Ziopharm Oncology, Inc.) a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient’s immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is based in Houston, Texas.

Recent Posts

See what the community is saying - click to see full post.